Physician profile
Jill Denise Avery
NPI 1538259015
$116,888.97
in general payments reported to CMS, 2019-2025
7 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $56K · 2024: $44K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $82K · Travel and Lodging: $31K · Food and Beverage: $2,977 · Consulting Fee: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,854.00 |
| Travel and Lodging | $31,458.12 |
| Food and Beverage | $2,976.85 |
| Consulting Fee | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $101,831.16 | 2023-2025 | Zepzelca |
| Pharmacyclics LLC, An Abbvie Company | $7,587.03 | 2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $6,214.50 | 2023-2024 | Reblozyl, Onureg |
| Celgene Corporation | $600.00 | 2023-2024 | Reblozyl |
| Janssen Biotech, INC. | $423.26 | 2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $125.01 | 2023 | Libtayo |
| Glaxosmithkline, LLC. | $108.01 | 2024 | Ojjaara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Avery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.